A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT02324569
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT02324569
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02324569. Randomized; quadruple masking; primary purpose treatment. Start 2014-12-27 (actual); primary completion 2016-12-28 (actual). Results posted on 2019-02-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- SYR-472
- Intervention (Drug)
- Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct02324569- Content hash
3d470269b248997fcdc2dcd587acee9d58a811f25c5aa0d35f32b10939a0729e